Elevated plasma osteoprotegerin levels are associated with venous thrombosis and bleeding in patients with polycythemia vera

Thrombosis and Haemostasis

Volumn 93, Issue 1, 2005, Pages 70-75

  Kees, Mathias ^a   Wiesbauer, Franz ^a   Gisslinger, Bettina ^a   Wagner, Renate ^a   Shehata, Medhat ^a   Gisslinger, Heinz ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bleeding; Osteoprotegerin; Polycythemia vera; Thrombosis; Vascular complications

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; BUSULFAN; HYDROXYUREA; OSTEOPROTEGERIN; PIPOBROMAN; PLACEBO; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOEMBOLISM; VASCULAR DISEASE; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; FEMALE; GLYCOPROTEINS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; POLYCYTHEMIA VERA; PROSPECTIVE STUDIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOSIS;

EID: 12344327714     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-06-0394     Document Type: Article

References (29)

1. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-64.
2. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272-90.
3. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978; 2: 1219-22.
4. Ruggeri M, Gisslinger H, Tosetto A; et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002; 71: 1-6.
5. Gisslinger H, Rodeghiero F, Ruggeri M, et al. Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Br J Haematol 1999; 105: 551-5.
6. Michiels JJ. Erythromelalgia and thrombocythemia: a disease of platelet prostaglandin metabolism. Semin Thromb Hemost 1997; 23: 335-8.
7. Neuntoufl T, Heher S, Stefenelli T, et al. Endothelial dysfunction in patients with polycythaemia vera. Br J Haematol 2001; 115: 354-9.
8. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261-6.
9. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
10. Jono S, Ikari Y, Shioi A et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106:1192-4.
11. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-7.
12. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 549-53.
13. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
14. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
15. Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000; 103: 41-50.
16. Bucay N, Sarosi I, Dunstan CR et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-8.
17. Kim HH, Shin HS, Kwak HJ, et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. FASEB J 2003; 17: 2163-5.
18. Collin-Osdoby P, Rothe L, Anderson F, et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001; 276: 20659-72.
19. Zhang J, Fu M, Myles D et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002; 521: 180-4.
20. Tan KB, Harrop J, Reddy M, et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997; 204: 35-46.
21. Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88: 1024-8.
22. Knudsen ST, Foss CH, Poulsen PL, et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003; 149: 39-42.
23. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombo-cythemia. Semin Hematol 1999; 36: 9-13.
24. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-24.
25. Rothman K, Greenland S. Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins, 1998: 255-7.
26. Clayton D, Hills M. Statistical Models in Epidemiology. Oxford: Oxford University Press; 1993.
27. Chagraoui H, Tulliez M, Smayra T et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood 2003; 101:2983-9.
28. Chagraoui H, Sabri S, Capron C, et al. Expression of osteoprotegerin mRNA and protein in routine megakaryocytes. Exp Hematol 2003; 31: 1081-8.
29. Malyankar UM, Scatena M, Suchland KL, et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000; 275: 20959-62.